APC-Labeled Human BCMA / TNFRSF17 Protein, His Tag (Site-specific conjugation)

After Fc receptor blockade, the whole blood only control (Figure A) and the whole blood spiked with CAR-T cells (Figures B, C, and D) were first stained with anti-CD45 antibody, anti-CD3 antibody, and APC-Labeled Human BCMA/TNFRSF17 Protein, His Tag (Site-specific conjugation) (Cat. BCA-HA2H5), followed by 7-AAD staining. The data were analyzed using FCS Express 7 software (routinely tested). CAR-T cells were identified as APC-positive events within the live CD45⁺CD3⁺ (or CD45⁺) lymphocyte population. In panels B, C, and D, the proportions of CD45⁺ CAR⁺ cells were approximately 20%, 10%, and 1%, respectively, consistent with the theoretical spike‑in values of 22.07%, 11.33%, and 1.13%.

5e5 of anti-BCMA CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human BCMA, His Tag (Cat. No. BCA-HA2H5) and negative control protein respectively. APC signal was used to evaluate the binding activity (QC tested).

After Fc receptor blockade, the whole blood only control (Figure A) and the whole blood spiked with CAR-T cells (Figures B, C, and D) were first stained with anti-CD45 antibody, anti-CD3 antibody, and APC-Labeled Human BCMA/TNFRSF17 Protein, His Tag (Site-specific conjugation) (Cat. BCA-HA2H5), followed by 7-AAD staining. The data were analyzed using FCS Express 7 software (routinely tested). CAR-T cells were identified as APC-positive events within the live CD45⁺CD3⁺ (or CD45⁺) lymphocyte population. In panels B, C, and D, the proportions of CD45⁺ CAR⁺ cells were approximately 20%, 10%, and 1%, respectively, consistent with the theoretical spike‑in values of 22.07%, 11.33%, and 1.13%.

5e5 of anti-BCMA CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human BCMA, His Tag (Cat. No. BCA-HA2H5) and negative control protein respectively. APC signal was used to evaluate the binding activity (QC tested).